WallStSmart

Crown Castle (CCI)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Crown Castle generates 81543% more annual revenue ($4.21B vs $5.16M). CCI leads profitability with a 25.1% profit margin vs 5.2%. EUDA trades at a lower P/E of 26.6x. CCI earns a higher WallStSmart Score of 51/100 (C-).

CCI

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 7.0Value: 4.7Quality: 4.5
Piotroski: 3/9Altman Z: -0.67

EUDA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 3.0Value: 5.3Quality: 5.8
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCIOvervalued (-13.3%)

Margin of Safety

-13.3%

Fair Value

$75.96

Current Price

$88.78

$12.82 premium

UndervaluedFair: $75.96Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCI3 strengths · Avg: 9.7/10
Operating MarginProfitability
47.7%10/10

Strong operational efficiency at 47.7%

Debt/EquityHealth
-18.0810/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.1%9/10

Keeps 25 of every $100 in revenue as profit

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
60.2%10/10

Revenue surging 60.2% year-over-year

Debt/EquityHealth
-0.6210/10

Conservative balance sheet, low leverage

Areas to Watch

CCI4 concerns · Avg: 2.8/10
P/E RatioValuation
36.2x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-206.7%2/10

ROE of -206.7% — below average capital efficiency

Revenue GrowthGrowth
-4.8%2/10

Revenue declined 4.8%

EUDA4 concerns · Avg: 3.5/10
P/E RatioValuation
26.6x4/10

Moderate valuation

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.08M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CCI

The strongest argument for CCI centers on Operating Margin, Debt/Equity, Profit Margin. Profitability is solid with margins at 25.1% and operating margin at 47.7%. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 60.2% demonstrates continued momentum.

Bear Case : CCI

The primary concerns for CCI are P/E Ratio, Piotroski F-Score, Return on Equity.

Bear Case : EUDA

The primary concerns for EUDA are P/E Ratio, EPS Growth, Market Cap.

Key Dynamics to Monitor

CCI profiles as a declining stock while EUDA is a hypergrowth play — different risk/reward profiles.

CCI carries more volatility with a beta of 0.96 — expect wider price swings.

EUDA is growing revenue faster at 60.2% — sustainability is the question.

CCI generates stronger free cash flow (452M), providing more financial flexibility.

Bottom Line

CCI scores higher overall (51/100 vs 31/100), backed by strong 25.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crown Castle

REAL ESTATE · REIT - SPECIALTY · USA

Crown Castle is a real estate investment trust and provider of shared communications infrastructure in the United States. Its network includes over 40,000 cell towers and nearly 80,000 route miles of fiber supporting small cells and fiber solutions. Headquartered in Houston, Texas, the company has 100 offices nationwide.

Visit Website →

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies addressing rare diseases and unmet medical needs. Leveraging cutting-edge technologies and a robust clinical pipeline, the company focuses on pivotal areas such as supportive care and immune modulation. With a strong commitment to research and development, EUDA is poised to advance healthcare innovation and enhance patient outcomes, while striving to broaden access to essential medical therapies through its promising clinical initiatives.

Visit Website →

Want to dig deeper into these stocks?